To promote sustained learning and increase retention as compared to traditional passive learning techniques, InteLearn leverages cognitive science with active learning methods such as pre-test priming, peer learning, and recall
MEDNIVA, an exclusive licensee of Duke-NUS Medical School, launched a new science-based method of learning to the global healthcare industry, which has been proven to be more effective than traditional education practices and can dramatically transform the way the industry educates its stakeholders.
InteLearn is an exclusive teaching methodology, leveraging cognitive science with active learning methods such as pre-test priming, peer learning, and recall. InteLearn has been shown to promote sustained learning and increase retention as compared to traditional passive learning techniques.
“Most adults have attention spans of about six to 10 minutes, meaning they can forget up to 80 per cent of a traditional one hour lecture. Cognitive science has found that customised testing is 40 per cent more effective than re-reading and other passive methods because it helps reinforce the information for better recall in the future. These and many other insights into how the human brain learns form the basis of InteLearn,” said Dr. Ranga Krishnan , academic advisor and co-founder of MEDNIVA.
InteLearn was recently validated by a large group of senior medical and commercial leaders at a top 10 multinational pharma company with a highly customised, in-depth engagement with MEDNIVA.
“Results were phenomenal, and participants were significantly more knowledgeable, credible, and persuasive after the MEDNIVA engagement. This truly demonstrates the benefits of science-led learning for a science-led industry,” said Dr Neil MacIntyre, pulmonologist and professor of medicine at Duke University Medical Center in Durham, North Carolina, US, who was actively involved in this engagement.
“Duke-NUS Medical School is proud to support the launch of MEDNIVA and bring to the global healthcare industry what has worked so well with our medical students,” said Dr Thomas Coffman, Dean of Duke-NUS Medical School in Singapore.
The MEDNIVA teaching methodology, InteLearn, was derived from the basis of teaching at both Duke-NUS Medical School (Singapore) and Duke University School of Medicine (US).
An engagement with MEDNIVA is highly customized for both internal and external stakeholders, such as the salesforce, marketing teams, medical directors, physicians, pharmacists, nurses, and payers. The content is customised across multiple therapeutic areas with renowned faculty from Duke University and other leading global institutions to meet specific learning objectives. Live sessions include individual and team tests, case studies, active discussions, and simulations. There are no traditional lectures in an engagement with MEDNIVA.
“Healthcare companies are already spending heavily on educating their stakeholders, yet most of those investments are highly inefficient and do not deliver optimal learning outcomes. It’s akin to education malpractice. MEDNIVA offers a unique alternative to traditional marketing, sales, and medical education investments. We are confident that our patent-pending learning solution will disrupt education in the healthcare industry and optimize industry investments, while improving healthcare outcomes for both professionals and patients,” said Sumeet Sud, Chief Executive Officer and co-founder of MEDNIVA.